naloxone | 72561-63-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: naloxone
• 英文别名: N-Allyldihydronormorphinone；(4R,4aR,7aR,12bS)-9-hydroxy-3-prop-2-enyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
• CAS: 72561-63-8
• 化学式: C₁₉H₂₁NO₃
• 分子量: 311.381
• InChiKey: BNDBOABKEVYVJX-ATNYCFDYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  17-allyl-4,5α-epoxy-3-methoxy-morphinan-6-one 在 吡啶盐酸盐 作用下， 生成 naloxone
  参考文献：
  名称：

  N-Substituted Epoxymorphinans

  摘要：

  DOI：

  10.1021/ja01116a024

文献信息

• DENDRIMER CONJUGATES
  申请人：Baker, JR. James R.

  公开号：US20100160299A1

  公开（公告）日：2010-06-24

  The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.

  本发明涉及新型的治疗和诊断树状分子。具体而言，本发明涉及树状分子-连接剂共轭物、其合成方法、包含该共轭物的组合物，以及利用该共轭物的系统和方法（例如，在诊断和/或治疗设置中（例如，用于传递治疗剂、成像和/或靶向剂（例如，在疾病（例如，癌症）诊断和/或治疗、疼痛治疗等方面））。因此，本发明的树状分子-连接剂共轭物还可以包括一个或多个用于靶向、成像、感知和/或提供治疗或诊断材料以及/或监测治疗反应的组分。
• ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT
  申请人：Wang Hoau-Yan

  公开号：US20140017699A1

  公开（公告）日：2014-01-16

  An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ 42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7 - 12. An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.
• US8889635B2
  申请人：——

  公开号：US8889635B2

  公开（公告）日：2014-11-18
• US8980907B2
  申请人：——

  公开号：US8980907B2

  公开（公告）日：2015-03-17
• US9500640B2
  申请人：——

  公开号：US9500640B2

  公开（公告）日：2016-11-22